Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03826147
Other study ID # 18-0364
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 1, 2019
Est. completion date July 2024

Study information

Verified date May 2023
Source University of Colorado, Boulder
Contact Hannah Lally
Phone 303-735-6410
Email beetrootstudy@colorado.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nitric oxide (NO) is an essential molecule in the body that is decreased in patients with chronic kidney disease (CKD), leading to reductions in vascular, movement ("motor") and cognitive functions. This study will determine if daily oral supplementation (3 months) with a supplement that increases NO in the body, i.e., nitrate-rich beetroot juice, improves vascular, motor and cognitive function in patients with CKD; this study will also provide insight into the biological reasons (mechanisms) by which supplementation with nitrate-rich beetroot juice improves vascular function in these patients. Overall, this research will provide scientific evidence supporting the use of nitrate-rich beetroot juice for preserving physiological function and preventing co-morbid clinical conditions and disability in CKD.


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date July 2024
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - CKD stage II-IV (eGFR using the Modification of Diet in Renal Disease (MDRD) prediction equation 20-90 mL/min/1.73m2; stable renal function in the past 3 months) - Ability to give informed consent - Albumin > 3.0 g/dL - Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 6 min, climb 10 stairs) - Free from alcohol dependence or abuse, as defined by the American Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders (DSM-V) - Mini-mental state examination score >21 (rationale: to screen for subjects with major cognitive impairment) - Blood pressure (BP) >100/60 mmHg for past 3 months (rationale: blood pressure below 100/60 mmHg may elevate the normally small risk of hypotension with nitrate supplementation) - Not taking medications that will interfere with administered medications (e.g., sildenafil interacts with nitroglycerin) - Body mass index (BMI) <40 kg/m2 (vascular function measurements can be inaccurate in severely obese patients) Exclusion Criteria: - Life expectancy <1 year - Uncontrolled hypertension, defined as blood pressure > 160/100 mmHg in the past 3 months - History of severe liver disease - History of severe congestive heart failure (i.e., ejection fraction < 35%) - History of hospitalizations within the last 3 months - Active infection or antibiotic therapy - Warfarin use - Vasculitis requiring immunosuppressive therapy within the last year - High dietary nitrate intake or current nitrate/nitrite supplementation; hypersensitivity to nitrates or nitrites - Glucose-6-phosphate dehydrogenase deficiency or blood methemoglobin >2% - Unwilling to abstain from use of mouthwash or other oral hygiene practices (e.g., tongue scraping) outside of teeth brushing that disrupt the oral microbiome and would interfere with nitrate conversion to nitrite - Blood donation within 8 weeks prior to enrolling in the study; unwilling to abstain from donating blood for 8 weeks after completing the study

Study Design


Intervention

Dietary Supplement:
Nitrate-rich beetroot juice
Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
Nitrate-depleted beetroot juice
Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).

Locations

Country Name City State
United States Integrative Physiology of Aging Laboratory Boulder Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Boulder

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Motor function composite score Multiple domains of motor function (including endurance, strength, dexterity) assessed using the NIH Toolbox Motor Battery (aggregated into one reported value) Baseline, 3 months
Other Fluid cognition composite score Multiple domains of cognitive function (including executive function, memory, processing speed) assessed using the NIH Toolbox Cognitive Battery (aggregated into one reported value) Baseline, 3 months
Primary Change in vascular endothelial function as measured by brachial artery flow-mediated dilation Baseline, 3 months
Primary Change in aortic stiffness as measured by carotid-femoral pulse wave velocity Baseline, 3 months
Secondary Change in oxidative stress-associated suppression of endothelial function assessed as the increase in brachial artery flow-mediated dilation following an ascorbic acid infusion The influence of oxidative stress on brachial artery flow-mediated dilation will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline Baseline, 3 months
Secondary Change in endothelial cell markers of oxidative stress Endothelial cell nitrotyrosine levels will be determined Baseline, 3 months
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4